Cytomegalovirus Infection market size to register incremental growth during the forecast period (2024-2034). Companies are actively developing new CMV therapies.

Cytomegalovirus (CMV) Infection Market Forecast

1 Key Insight
 
2 Report Introduction
 
3 Executive Summary
 
4 Key Events
 
5&nbsp;Cytomegalovirus Infections Epidemiology and Market Forecast Methodology
 
6 Cytomegalovirus (CMV) Infections: Market Overview at a Glance
 
6.1 Total Market Share (%) Distribution of Cytomegalovirus Infections in 2020
 
6.2 Total Market Share (%) Distribution of Cytomegalovirus Infections in 2034
 
7 Disease Background and Overview: Cytomegalovirus Infections
 
7.1 Introduction
 
7.2 Classification of Cytomegalovirus Infections
 
7.3 Causes of Cytomegalovirus infections
 
7.4 Symptoms of Cytomegalovirus infections
 
7.5 Risk factors of Cytomegalovirus infections
 
7.6 Pathophysiology of Cytomegalovirus infections
 
7.7 Diagnosis of Cytomegalovirus infections
 
8&nbsp;Cytomegalovirus Infections Treatment and Management
 
8.1 Treatment Guidelines
 
9&nbsp;Cytomegalovirus Infections Epidemiology and Patient Population
 
9.1 Key Findings
 
9.2 Assumptions and Rationale
 
9.3 Total Diagnosed Cytomegalovirus Patients in 7MM
 
9.4 United States
 
9.4.1 Total Diagnosed Cases of Cytomegalovirus Infection in the United States
 
9.4.2 Number of Infants Born With Congenital Cytomegalovirus in the United States
 
9.4.3 Cytomegalovirus Patients among Hematopoietic Stem Cell Transplants (HSCT) in the United States
 
9.4.4 Number of Cytomegalovirus Patients Among Solid Organ Transplants (SOT) in the United States
 
9.4.5 Number of Refractory Cytomegalovirus Patients after HSCT/SOT in the United States
 
9.4.6 Cytomegalovirus Retinitis Among Humanimmunodeficiency Patients in the United States
 
9.5 EU4 and the UK
 
9.5.1 Total Diagnosed Cases of Cytomegalovirus Infection in EU4 and the UK
 
9.5.2 Number of Infants Born With Congenital Cytomegalovirus in EU4 and the UK
 
9.5.3 Cytomegalovirus Patients Among Hematopoietic Stem Cell Transplants (HSCT) in EU4 and the UK
 
9.5.4 Number of Cytomegalovirus Patients Among Solid Organ Transplants (SOT) in EU4 and the UK
 
9.5.5 Number of Refractory Cytomegalovirus Patients after HSCT/SOT in EU4 and the UK
 
9.5.6 Cytomegalovirus Retinitis among HIV Patients in EU4 and the UK
 
9.6 Japan
 
9.6.1 Total Diagnosed Cases of Cytomegalovirus Infection in Japan
 
9.6.2 Number of Infants Born With Congenital Cytomegalovirus in Japan
 
9.6.3 Cytomegalovirus Patients Among Hematopoietic Stem Cell Transplants (HSCT) in Japan
 
9.6.4 Number of Cytomegalovirus Patients Among Solid Organ Transplants (SOT) in Japan
 
9.6.5 Number of Refractory Cytomegalovirus Patients after HSCT/SOT in Japan
 
9.6.6 Cytomegalovirus Retinitis among HIV Patients in Japan
 
10 Cytomegalovirus infections Patient Journey
 
11 Cytomegalovirus infections Marketed Products
 
11.1 Key Competitors
 
11.2 VALCYTE: Roche/Cheplapharm
 
11.2.1 Product Description
 
11.2.2&nbsp;Cytomegalovirus Infections Mechanism of Action
 
11.2.3 Regulatory Milestones
 
11.2.4 Safety and Efficacy
 
11.2.5 Product Profile
 
11.3 LIVTENCITY (Maribavir): Takeda Pharmaceuticals
 
11.3.1 Product Description
 
11.3.2&nbsp;Cytomegalovirus Infections Mechanism of Action
 
11.3.3 Regulatory Milestones
 
11.3.4 Safety and Efficacy
 
11.3.5 Product Profile
 
To be continued in report&hellip;
 
12 Cytomegalovirus infections Emerging Drugs
 
12.1 Key competitors
 
12.2 Triplex: Helocyte
 
12.2.1 Product Description
 
12.2.2 Other Developmental Activities
 
12.2.3 Clinical Development
 
12.2.4 Safety and Efficacy
 
12.2.5 Product Profile
 
12.3 mRNA-1647: Moderna
 
12.3.1 Product Description
 
12.3.2 Other Developmental Activities
 
12.3.3 Clinical Development
 
12.3.4 Safety and Efficacy
 
12.3.5 Product Profile
 
To be continued in report&hellip;
 
13 Cytomegalovirus Infection: Seven Major Market Analysis
 
13.1 Key Findings
 
13.2 Cytomegalovirus infections Market Outlook
 
13.3 Conjoint Analysis
 
13.4 Key Market Forecast Assumptions
 
13.5 Market Size of Cytomegalovirus Infection in the 7MM
 
13.6 United States
 
13.6.1 Total Market Size of Cytomegalovirus Infection in the United States
 
13.6.2 Market Size of Cytomegalovirus Infection by Therapies in the United States
 
13.7 EU4 and the UK
 
13.7.1 Total Market size of Cytomegalovirus Infection in the EU4 and the UK
 
13.7.2 Market Size of Cytomegalovirus Infection by Therapies in the EU4 and the UK
 
13.8 Japan Market
 
13.8.1 Total Market Size of Cytomegalovirus Infection in Japan
 
13.8.2 Market Size of Cytomegalovirus Infection by Therapies in Japan
 
14 Cytomegalovirus infections Unmet Needs
 
15 SWOT Analysis
 
16 KOL Views
 
17&nbsp;Cytomegalovirus Infections Market Access and Reimbursement
 
17.1 United States
 
17.2 EU4 and the UK
 
17.3 Japan
 
18 Appendix
 
18.1 Bibliography
 
18.2 Report Methodology
 
19 DelveInsight Capabilities
 
20 Disclaimer
 
21 About DelveInsight

DelveInsight's “Cytomegalovirus Infections Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of Cytomegalovirus Infections epidemiology, market, and clinical development in Cytomegalovirus Infections. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Cytomegalovirus Infections therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain ), and the United Kingdom, and Japan.

Cytomegalovirus (CMV) Infection Market

Cytomegalovirus (CMV) Infection - Market Insight, Epidemiology And Market Forecast - 2034

Cytomegalovirus (CMV) Infection Market Forecast, 2034 report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends in 7MM.